The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations
- PMID: 12187499
- DOI: 10.1310/X6B5-9K42-E25N-F680
The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations
Abstract
Purpose: To compare the efficacy and tolerance of a stavudine (d4T), didanosine (ddI), efavirenz (EFV), and abacavir (ABC) combination regimen with an identical regimen plus hydroxyurea (HU), or plus HU and interleukin-2 (IL-2), in patients failing protease inhibitor-based combinations and naive of EFV and ABC.
Method: This was a randomized prospective trial in 69 HIV-infected patients recruited in one clinical center. Antiretroviral drugs were administered at standard doses according to weight. HU was added at week 6 at 500 mg twice daily. Three courses of IL-2 were given subcutaneously at 4.5 MU twice daily for 5 consecutive days, between weeks 24 and 40. The proportion of patients reaching plasma HIV-1 RNA <200 and <50 copies/mL was compared in the three trial groups at weeks 6, 24, and 48 using intent-to-treat and as-treated analyses. CD4+ T-cell count changes from baseline were also assessed at the same time points, along with anthropometric and metabolic measurements.
Results: After 48 weeks, only 25% of patients receiving antiretrovirals had plasma HIV-1 RNA <200 copies/mL versus 59.1% in the group receiving HU and 56.5% in the group receiving HU and IL-2 (intent-to-treat; p <.01). At the 50 copies/mL cutoff, the results were 20.8%, 54.5%, and 47.8%, respectively. Most treatment discontinuations were due to failure in the first group and adverse events in the two others. A median decline of 27 CD4+ cells was observed in patients receiving antiretrovirals plus HU, against a gain of 78-118 cells at week 48 in patients receiving antiretrovirals alone or in combination with HU and IL-2. More patients were affected by clinical fat atrophy symptoms at week 48 than at baseline. Additionally, a trend toward increased cholesterol levels was observed throughout the study.
Conclusion: During this trial, virologic response in patients failing previous regimens was clearly enhanced by the addition of HU, despite d4T and ddI recycling. Although adverse events were more frequent in the HU-containing arms, no unexpected toxicity was observed and the blunted CD4 response prompted by HU was corrected by the addition of IL-2. The combination of HU with reverse transcriptase inhibitors can therefore be regarded as a valuable alternative for patients with few remaining therapeutic options.
Similar articles
-
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.BMC Infect Dis. 2005 Apr 8;5:23. doi: 10.1186/1471-2334-5-23. BMC Infect Dis. 2005. PMID: 15819974 Free PMC article. Clinical Trial.
-
Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.AIDS Res Hum Retroviruses. 2004 Sep;20(9):916-26. doi: 10.1089/aid.2004.20.916. AIDS Res Hum Retroviruses. 2004. PMID: 15597521 Clinical Trial.
-
Switch to efavirenz in a protease inhibitor-containing regimen.HIV Clin Trials. 2001 May-Jun;2(3):200-4. doi: 10.1310/X9BK-C45Q-HQKJ-WJ4N. HIV Clin Trials. 2001. PMID: 11590528 Clinical Trial.
-
Delavirdine: a review of its use in HIV infection.Drugs. 2000 Dec;60(6):1411-44. doi: 10.2165/00003495-200060060-00013. Drugs. 2000. PMID: 11152019 Review.
-
Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.Drug Saf. 2003;26(9):605-24. doi: 10.2165/00002018-200326090-00002. Drug Saf. 2003. PMID: 12814330 Review.
Cited by
-
Hydroxyurea for the Treatment of Psoriasis including in HIV-infected Individuals: A Review.Psoriasis Forum. 2011 Fall;17(3):180-187. Psoriasis Forum. 2011. PMID: 25346593 Free PMC article.
-
Drug-induced reactivation of apoptosis abrogates HIV-1 infection.PLoS One. 2013 Sep 23;8(9):e74414. doi: 10.1371/journal.pone.0074414. eCollection 2013. PLoS One. 2013. PMID: 24086341 Free PMC article.
-
Curing HIV: lessons from cancer therapy.Curr Opin HIV AIDS. 2013 May;8(3):224-9. doi: 10.1097/COH.0b013e32835ef0a1. Curr Opin HIV AIDS. 2013. PMID: 23454863 Free PMC article. Review.
-
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.BMC Infect Dis. 2005 Apr 8;5:23. doi: 10.1186/1471-2334-5-23. BMC Infect Dis. 2005. PMID: 15819974 Free PMC article. Clinical Trial.
-
Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review.Ther Adv Musculoskelet Dis. 2020 Sep 3;12:1759720X20947296. doi: 10.1177/1759720X20947296. eCollection 2020. Ther Adv Musculoskelet Dis. 2020. PMID: 32952617 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials